360 related articles for article (PubMed ID: 7046933)
1. Trial of AMSA in acute leukemia.
Dupont JC; Garay GE; Scaghone C; Pavlovsky S; Woodley PV
Cancer Treat Rep; 1982 Jul; 66(7):1596-7. PubMed ID: 7046933
[No Abstract] [Full Text] [Related]
2. AMSA therapy for children with lymphoblastic malignancy.
Hutter JJ; Meyskens FL
Cancer Treat Rep; 1982 Mar; 66(3):593-4. PubMed ID: 6949644
[No Abstract] [Full Text] [Related]
3. Amsacrine in refractory acute leukemia.
Griffin JD; Maguire ME; Mayer RJ
Cancer Treat Rep; 1985; 69(7-8):787-9. PubMed ID: 3860296
[TBL] [Abstract][Full Text] [Related]
4. AMSA--a promising new agent in refractory acute leukemia.
Lawrence HJ; Ries CA; Reynolds RD; Lewis JP; Koretz MM; Torti FM
Cancer Treat Rep; 1982 Jul; 66(7):1475-8. PubMed ID: 7046928
[TBL] [Abstract][Full Text] [Related]
5. m-AMSA: phase II trial in advanced lymphoma and leukemia.
Case DC
Am J Clin Oncol; 1984 Aug; 7(4):357-60. PubMed ID: 6588746
[TBL] [Abstract][Full Text] [Related]
6. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
Weil M; Auclerc MF; Schaison G; Auclerc G; Daubrisson A; Degos L; Caro J; Marty M; Jacquillat GI
Nouv Presse Med; 1982 Oct; 11(39):2911-4. PubMed ID: 6755389
[TBL] [Abstract][Full Text] [Related]
7. [Case of refractory acute myeloblastic leukemia who achieved complete remission by a new anti-leukemic agent, 4'-(9-acridinylamino) methanesulfon-m-anisidide (AMSA)].
Nagura E; Kawashima K; Suzuki H; Ohno R; Yamada K; Yokomaku S; Ogawa M
Rinsho Ketsueki; 1983 May; 24(5):632-8. PubMed ID: 6577212
[No Abstract] [Full Text] [Related]
8. Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group.
Winton EF; Hearn EB; Vogler WR; Johnson L; Logan T; Raney M
Cancer Treat Rep; 1983 Nov; 67(11):977-80. PubMed ID: 6580070
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of amsacrine gluconate in refractory leukemia.
Omura GA; Winton EF; Vogler WR; Zuckerman KS; Grillo-Lopez AJ
Cancer Treat Rep; 1983 Dec; 67(12):1131-2. PubMed ID: 6580948
[TBL] [Abstract][Full Text] [Related]
10. High-dose AMSA and autologous bone marrow transplantation in relapsed acute leukemia.
Zander AR; Vellekoop L; Dicke KA; Keating MJ; McCredie KB; Legha SS; Spitzer G; Verma D; Bodey GP
Cancer Treat Rep; 1982 Nov; 66(11):1991-2. PubMed ID: 6754077
[No Abstract] [Full Text] [Related]
11. A phase I and II study of m-AMSA in acute leukaemia.
Slevin ML; Shannon MS; Prentice HG; Goldman AJ; Lister TA
Cancer Chemother Pharmacol; 1981; 6(2):137-40. PubMed ID: 6946878
[TBL] [Abstract][Full Text] [Related]
12. Acute electrocardiographic changes induced by amsacrine.
Shinar E; Hasin Y
Cancer Treat Rep; 1984 Sep; 68(9):1169-72. PubMed ID: 6592038
[TBL] [Abstract][Full Text] [Related]
13. Amsacrine alone or in combination with 5-azacytidine and etoposide in refractory or relapsed acute non lymphoblastic leukemia (ANLL).
Carella AM; Santini G; Martinengo M; Nati S; Giordano D; Congiu A; Cerri R; Damasio E; Risso M; Rossi E
Haematologica; 1985; 70(1):39-43. PubMed ID: 2408974
[No Abstract] [Full Text] [Related]
14. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.
Legha SS; Keating MJ; McCredie KB; Bodey GP; Freireich EJ
Blood; 1982 Aug; 60(2):484-90. PubMed ID: 6953987
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with amsacrine (AMSA) and cyclocytidine in refractory childhood leukemia: preliminary observations of a phase II study.
Miller LP; Miller DR; Tan CT
Cancer Treat Rep; 1983 May; 67(5):439-43. PubMed ID: 6189604
[No Abstract] [Full Text] [Related]
16. Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.
Arlin ZA
Cancer Treat Rep; 1983 Nov; 67(11):967-70. PubMed ID: 6357436
[No Abstract] [Full Text] [Related]
17. Fatal hepatotoxicity associated with AMSA therapy.
Appelbaum FR; Shulman HM
Cancer Treat Rep; 1982 Oct; 66(10):1863-65. PubMed ID: 6957265
[No Abstract] [Full Text] [Related]
18. Results of induction and consolidation treatment with intermediate and high-dose ara-C and m-AMSA containing regimens in patients with primarily failed or relapsed acute leukemia and non-Hodgkin's lymphoma.
Peters WG; Willemze R; Colly LP
Scand J Haematol Suppl; 1986; 44():7-16. PubMed ID: 3515513
[No Abstract] [Full Text] [Related]
19. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial of 4'-(9-acridinylamino) methanesulphon-m-anisidide (m-AMSA) in the treatment of advanced non-Hodgkin's lymphomas.
Abate G; Villari P; Comella P; D'Aprile M; Castello G; Silvestro P; Zarrilli D; Pergola M
Haematologica; 1985; 70(1):35-8. PubMed ID: 3924754
[No Abstract] [Full Text] [Related]
[Next] [New Search]
